Skip to main content

Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ: ARWR · IEX Real-Time Price · USD
73.96 2.29 (3.20%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap7.73B
Revenue (ttm)138.29M
Net Income (ttm)-140.85M
Shares Out104.53M
EPS (ttm)-1.07
PE Ration/a
Forward PE111.11
Dividendn/a
Ex-Dividend Daten/a
Volume575,850
Open72.32
Previous Close71.67
Day's Range71.05 - 74.77
52-Week Range57.92 - 93.66
Beta1.26
AnalystsBuy
Price Target87.92 (+18.9%)
Earnings Daten/a

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Pha...

IndustryBiotechnology
IPO DateJun 16, 1993
CEOChristopher Anzalone
Employees329
Stock ExchangeNASDAQ
Ticker SymbolARWR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 87.92, which is an increase of 18.88% from the latest price.

Price Target
$87.92
(18.88% upside)
Analyst Consensus: Buy

News

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

1 week ago - Business Wire

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

2 weeks ago - The Motley Fool

Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results and hosts a webcast to discuss the year

2 weeks ago - Business Wire

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals and GlaxoSmithKline sign exclusive license agreement for RNAi candidate ARO-HSD against NASH

2 weeks ago - Business Wire

Earnings Outlook For Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.

2 weeks ago - Benzinga

Arrowhead Announces JNJ-75220795 in Development for NASH

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Janssen collaborating JNJ-75220795 in Development for NASH

3 weeks ago - Business Wire

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection at AASLD Liver Meeting

3 weeks ago - Business Wire

Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Presents Clinical Data on ARO-APOC3 for hypertriglyceridemia at AHA 2021

3 weeks ago - Business Wire

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data on Alpha-1 antitrypsin deficiency at AASLD Liver Meeting

3 weeks ago - Business Wire

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data on NASH at AASLD Liver Meeting

3 weeks ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results on November 22, 2021

1 month ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in November 2021 Conferences, AASLD, AHA, Jefferies, Piper Sandler

1 month ago - Business Wire

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Dis...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases and will hold a KOL webinar

1 month ago - Business Wire

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

1 month ago - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

2 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will participate in upcoming October 2021 conferences

2 months ago - Business Wire

Arrowhead Earns $10 Million Phase 1 Milestone Payment

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals earned a $10 million milestone from Janssen when RNAi candidate ARO-JNJ1 entered a Phase 1 clinical trial

2 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

3 months ago - Business Wire

Recap: Arrowhead Pharmaceuticals Q3 Earnings

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.29...

4 months ago - Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal 2021 third quarter results and holds a webcast and conference call

4 months ago - Business Wire

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Al...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead receives breakthrough therapy designation for ARO-AAT and announces full enrollment for SEQUOIA Phase 2 clinical trial

4 months ago - Business Wire

Arrowhead Pharmaceuticals: Buy the Dip?

This biotech underdog offers more than meets the eye.

4 months ago - The Motley Fool

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results

4 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

4 months ago - Business Wire

Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.

5 months ago - Benzinga